GlassScriptPhysician profile
Heidi Michelle Sapp
NPI 1205918075
$1,505.93
in general payments reported to CMS, 2019-2025
29 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $152 · 2021: $245 · 2022: $213 · 2023: $272 · 2024: $125 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $573.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $258.38 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Hologic Sales and Service, LLC | $148.52 | 2020-2024 | Myosure Tissue Removal Device, Acessa Provu System, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $135.81 | 2019-2025 | |
| Therapeuticsmd, INC. | $118.40 | 2019-2022 | |
| Minerva Surgical, INC | $101.00 | 2023-2025 | |
| Evofem Biosciences, INC. | $90.30 | 2021-2023 | Phexxi |
| Allergan, INC. | $74.09 | 2019 | |
| Optumhealth Care Solutions, LLC | $67.09 | 2023-2025 | Vivify Health Care Team Portal 001, Eitan Medical, Zyno Solutions |
| Sage Therapeutics, LLC | $50.52 | 2021-2024 | |
| Exeltis, USA INC. | $47.47 | 2021-2025 | Slynd |
| Shield Therapeutics INC | $43.18 | 2024-2025 | |
| Pfizer INC. | $39.24 | 2022-2024 | |
| Channel Medsystems, INC. | $35.52 | 2022 | |
| Avion Pharmaceuticals | $26.48 | 2021 | |
| Agile Therapeutics, INC. | $26.21 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $26.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $22.62 | 2019 | |
| Coopersurgical, INC. | $21.81 | 2025 | Paragard T 380a |
| Duchesnay USA Incorporated | $21.10 | 2019 | |
| Scynexis, INC. | $19.10 | 2022 | |
| Lupin INC. | $18.48 | 2020 | |
| Exact Sciences Corporation | $18.36 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $17.95 | 2019 | |
| Aspira Women'S Health INC | $17.36 | 2022 | |
| Astellas Pharma US INC | $17.20 | 2025 | Veozah |
| Meditrina | $17.10 | 2023 | |
| Roche Diagnostics Corporation | $15.29 | 2020 | |
| Organon LLC | $11.22 | 2025 | Nexplanon |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Sapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.